New biotech facility to bring 350 jobs to Dublin

pharmafile | February 14, 2018 | News story | Manufacturing and Production, Research and Development Dublin, Ireland, MSD, pharma 

MSD has announced plans to invest in a new biotechnology facility in Dublin which it claims will create 350 jobs in the Irish capital.

The plant will be built on property the company already owns – the site of its former facility in Swords, which was closed down in June last year, taking with it 570 jobs since 2013.

The news shows that MSD is committed to bolstering its operations in Ireland. The company already employs more than 1,700 staff across four sites in Dublin, Carlow, Cork and Tipperary, with operations in the country generating $5.8 billion in 2016.  

Last year, the firm announced plans to invest just under $350 million in its Carlow and Cork sites by 2020.

The move is part of a global investment plan to the tune of $12 billion which the company announced this month, around $10 billion of which will be spent in the US.

“This investment by MSD is a great vote of confidence in Ireland. MSD has been a tremendous success story in this country with plants located in several centres, providing valuable employment,” commented Speaking Ireland’s Minister for Business, Enterprise and Innovation, Heather Humphreys. “This new, cutting edge, Biotechnology facility will be a tremendous asset to our Pharma industry and will deepen the great partnership between the company and Ireland.”

Matt Fellows

Related Content


MSD announce new data from advanced renal cell carcinoma trial

Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) …

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Latest content